Connecticut

Wholesale Acquisition Cost Information for Connecticut Prescribing Practitioners and Pharmacists

In accordance with Connecticut Public Act No. 23-171, Partner Therapeutics is disclosing to prescribing practitioners and pharmacists in Connecticut certain required wholesale acquisition cost (WAC) pricing information for Partner Therapeutics-marketed legend drugs.

Please choose a product from the list, and select “WAC Information” below.

LEUKINE^® (sargramostim) for Injection, for Subcutaneous or Intravenous Use

BIZENGRI^® (zenocutuzumab – zbco) Injection for IV Use

WAC Information

Wholesale Acquisition Cost Information for Connecticut Prescribing Practitioners and Pharmacists

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC

Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])